REGN Regeneron Pharmaceuticals 10-Q 2026-09-30 section summaries

Regeneron (REGN) — Q3 and nine months ended September 30, 2026

Consolidated results

Revenue grew 36.3% in Q3 and 24.4% in 9M; collaboration revenue was the largest driver, rising 52.4% and 37.2%, respectively. Operating income rose 99.5% in Q3 and 47.7% in 9M, while net income grew 33.5% and 8.5%. Higher R&D spending and substantially lower investment gains tempered earnings growth.

Product and collaboration drivers

Combined U.S. EYLEA HD/EYLEA sales were $3,048.5M in 9M 2026 versus $3,301.5M in 9M 2025. Global Libtayo sales were $1,477.6M versus $1,026.8M, and global Lynozyfic sales were $46.7M versus $0.8M.

Sanofi collaboration profit share was $2,574.9M in Q3 2026 versus $1,455.5M, and $6,058.3M in 9M versus $3,755.7M. Bayer profit share declined to $211.5M from $311.9M in Q3 and $678.8M from $1,012.6M in 9M. Two customers accounted for 48% and 30% of Q3 gross product revenue (49% and 30% in Q3 2025); in 9M they accounted for 46% and 31% (51% and 26%).

After quarter-end, Regeneron amended its Sanofi collaboration to include four Regeneron-invented long-acting antibodies. It received a $1.0B upfront payment, to be recognized as Q4 2026 collaboration revenue, and is eligible for up to $7.0B in additional milestones; global profits on the new products will be shared equally.

Costs, cash flow and capital allocation

Nine-month acquired IPR&D included collaboration/licensing-related premiums and milestone payments; the 2025 period included an $80.0M Hansoh upfront payment. Regeneron reports one operating segment.

Operating cash flow was affected by a $1,850.5M increase in accounts receivable, compared with a $549.3M decrease in 9M 2025. Cash-flow share repurchases were $2,363.4M versus $2,766.9M; dividends paid were $290.3M versus $277.6M. Regeneron repurchased 3.2M shares in 9M versus 4.5M; a new $3.0B authorization was approved in April, with $2.157B remaining at September 30. Stock-based compensation expense was $756.2M versus $744.4M.

Balance sheet and investments

Derived tangible equity was $32,183.0M. Available-for-sale debt securities had $15,018.9M fair value against $15,182.8M amortized cost at September 30, with $167.9M gross unrealized losses and $4.0M gross unrealized gains. Net gains on marketable and other securities were $147.2M in 9M 2026 versus $967.6M in 9M 2025. Separately, equity-investment net gains were $143.2M versus $966.6M; Q3 gains were $57.7M versus $577.0M. Long-term debt fair value was $1,494M versus $1,576M.

Common shares issued increased from 137.6M at December 31, 2025 to 138.5M at September 30, 2026; treasury shares increased from 33.7M to 36.9M. Q3 weighted-average diluted shares were 105.6M versus 107.2M.

Litigation and other material developments

The company faces continuing legal and regulatory exposure, including EYLEA 2 mg and EYLEA HD patent challenges that could affect biosimilar protection; DOJ, state and qui tam matters involving patient assistance, prescriber remuneration and EYLEA reimbursement reporting; and related payor and securities litigation. Some matters remain pending or on appeal, and potential losses in certain proceedings cannot be estimated. A separate Dupixent product-liability MDL concerns allegations of T-cell lymphoma. In the Praluent antitrust case, a 2025 jury verdict awarded Regeneron $135.6M compensatory and $271.2M punitive damages; post-trial motions and requested relief remained pending.

In October 2026, Regeneron and Sanofi settled and dismissed a dispute over information-access and audit obligations under their Dupixent collaboration. The 2025 securities class action tied to DOJ allegations and EYLEA HD disclosures was dismissed in September 2026; the plaintiff appealed in October.

Regeneron (REGN) — Q3 and nine months ended September 30, 2026

Consolidated results

Revenue grew 36.3% in Q3 and 24.4% for 9M, while net income rose 33.5% and 8.5%, respectively. The slower 9M earnings growth reflects, in part, sharply lower investment gains compared with 2025.

Q3 revenue composition

Sanofi collaboration revenue increased substantially: Regeneron’s share of collaboration profits was $2.5749B, or 38% of Sanofi-recorded Dupixent and Kevzara sales, versus $1.4555B and 29% in Q3 2025. For 9M, the profit share was $6.0583B versus $3.7557B (34% versus 28% of sales). Higher Dupixent sales and repayment of Sanofi’s development balance contributed; 2025 comparisons also included development-expense reimbursements.

Global product sales provide additional context but are not all recorded as Regeneron revenue: Sanofi records Dupixent sales and Regeneron receives a profit share; Regeneron records U.S. EYLEA sales while Bayer records ex-U.S. sales and shares profits. Global Dupixent sales grew 35% to $6.5405B in Q3. EYLEA HD sales rose 63% to $1.0828B, while EYLEA sales fell 49% to $658.4M; combined global EYLEA HD/EYLEA sales declined 11% to $1.7412B (down 15% for 9M, versus 11% in Q3). The transition from EYLEA to HD and competitive pressure, including biosimilars, continue to weigh on EYLEA. Libtayo global sales rose 51% to $550.0M in Q3 and 44% for 9M.

Bayer collaboration profit share declined as ex-U.S. EYLEA sales weakened: Q3 sales were $642.7M versus $853.8M, and Regeneron’s share of profits after reimbursements was $211.5M versus $311.9M (33% versus 37% of sales). For 9M, the profit share was $678.8M versus $1.0126B (33% versus 38%).

Costs, cash flow and liquidity

For 9M, R&D was $4.9698B versus $4.2241B. Higher clinical manufacturing costs and investment in programs including linvoseltamab and cenvacibart/amrecibart contributed. Product gross margin was 82% in Q3 in both years, but 79% for 9M 2026 versus 82% in 2025, primarily because unabsorbed manufacturing costs arose during unanticipated repairs at the Limerick facility. Production returned to normal by June 30, 2026, without affecting product availability.

Q3 gains on marketable and other securities fell to $60.3M from $577.7M, a major factor in the lower non-operating income. At September 30, cash and cash equivalents plus current and noncurrent marketable securities totaled $18.8585B, compared with $18.8658B at December 31, 2025. Working capital was $14.5930B; long-term debt was $1.9870B, finance lease liabilities were $720.0M, and $750.0M remained available under the revolving credit facility. Full-year capital expenditures were expected to be $1.050B–$1.100B, supporting research and manufacturing expansions. Of the $3.0B repurchase authorization approved in April, $2.157B remained at September 30.

Developments and outlook

An October 2026 Sanofi amendment provided Regeneron a $1.0B upfront payment, to be recognized in Q4, and potential additional milestones of up to $7.0B. It adds four Regeneron-invented long-acting antibodies; three are expected to enter clinical studies in 2027. Development costs and profits on the licensed products are generally shared equally.

The pipeline had notable successes and setbacks. EYLEA HD received U.S. approval for dosing intervals up to 20 weeks in wet AMD and diabetic macular edema. Dupixent received additional U.S. and international approvals, while its EU bullous pemphigoid application was withdrawn and Phase 3 lichen simplex chronicus studies missed their primary endpoints. Libtayo received Japanese approval in cutaneous squamous cell carcinoma. Pasatru was approved by the FDA for FOP; Otarmeni also received FDA approval. The FDA clinical hold was removed for Phase 3 trials of nexiguran ziclumeran. Conversely, the fianlimab-plus-Libtayo Phase 3 study in first-line metastatic melanoma did not meet its primary endpoint; baloncibart’s Phase 2 sepsis-induced hypotension study also missed its primary endpoint. Regeneron and Sanofi discontinued itepekimab development in COPD and chronic rhinosinusitis.

April 2026 U.S. government agreements require most-favored-nation pricing for certain products, direct-purchase participation for Praluent, and free U.S. Otarmeni. In return, products are protected from Section 232 tariffs through January 2029, conditional on continued U.S. manufacturing and R&D investment. The commitments may affect U.S. product economics; other key uncertainties include competition, reimbursement, clinical and regulatory outcomes, commercialization, manufacturing capacity, and collaborator performance.

As of September 30, 2026, Regeneron reported no material changes in its market risks or in how it manages them compared with the disclosures in its 2025 Form 10-K, filed February 4, 2026. This section provides no additional market-risk metrics or specific exposure details.

Management, including the CEO and CFO, concluded that Regeneron’s disclosure controls and procedures were effective as of September 30, 2026. No change during the quarter materially affected, or was reasonably likely to materially affect, the company’s internal control over financial reporting. This section reported no financial metrics or other business developments.

Key business and revenue exposures

Regeneron’s results are concentrated in a small number of products and collaborations. U.S. EYLEA sales face sustained pressure from biosimilars, other VEGF inhibitors, and off-label compounded bevacizumab; the company says affordability constraints and loss of share to compounded bevacizumab affected EYLEA sales in FY2025. EYLEA’s U.S. regulatory exclusivity expired in May 2024, and biosimilars have launched in the U.S. and certain international markets. Regeneron cautions that it is uncertain whether EYLEA HD can offset further EYLEA declines. EYLEA HD’s U.S. protection depends on patents, and further biosimilar launches could affect both products and Bayer collaboration revenue.

Sanofi collaboration revenue primarily reflects Regeneron’s share of Dupixent profits, making Dupixent another major source of revenue concentration. Sanofi records U.S. Dupixent sales and leads payer negotiations; it also leads commercialization in many non-U.S. markets. Bayer supports EYLEA and EYLEA HD commercialization outside the U.S. and may terminate its agreement on six or twelve months’ notice, depending on circumstances. Losing either collaborator, or a major distributor, could disrupt sales; the two distributors also represent a significant portion of net trade receivables.

Pricing, access, and competition

Sales depend on coverage, reimbursement, patient affordability, and copay support. Prior authorization, step therapy, formularies, rebates, and other utilization controls can limit access. Government pricing programs and policy changes—including Medicare price negotiation and inflation rebates under the Inflation Reduction Act—add uncertainty. In April 2026, Regeneron entered U.S. Government Agreements to provide certain wholly owned products to Medicaid and price certain future medicines at no more than Most-Favored-Nation prices. The agreements are expected to reduce prices and reimbursement for certain products; in return, qualifying products are not expected to face Section 232 tariffs through January 2029, subject to conditions that include continued U.S. manufacturing and R&D investment.

Other competitive risks span Dupixent, Libtayo, Lynozyfic, Praluent, Evkeeza, Kevzara, and pipeline programs. Competitors’ established or developing medicines, biosimilars, gene and cell therapies, RNAi, and other modalities could reduce market share or limit pipeline opportunities. Regeneron also cites increasing competition from Chinese biotech and pharmaceutical companies. Commercial success depends not only on approval, but also on adoption, adequate coverage, differentiation, and the ability to supply products; injected or infused therapies may be less preferred than oral alternatives.

Development, regulatory, manufacturing, and legal risks

Clinical development is costly and uncertain: trials may fail to establish safety or efficacy, enroll adequately, or meet changing regulatory expectations. In May 2026, the Phase 3 fianlimab-plus-Libtayo trial in first-line metastatic melanoma did not meet its primary endpoint versus pembrolizumab monotherapy. FDA review or approvals may be delayed, narrowed, or conditioned on additional studies, warnings, or other requirements. Notable delays include the March 2024 and July 2025 CRLs for odronextamab applications and the October 2025 CRL for the EYLEA HD pre-filled syringe, related to third-party manufacturing inspection findings. Dupixent’s CSU approval was delayed nearly 18 months after an October 2023 CRL requesting additional efficacy data.

Safety issues may emerge in broader or longer-term use, leading to restrictions, recalls, or withdrawal of approval. Regeneron also faces patent challenges and litigation involving EYLEA and EYLEA HD, including post-grant review instituted in March 2026 for a patent relating to EYLEA HD. Loss of patent protection or market exclusivity could cause rapid sales declines.

Regeneron relies on internal facilities and third parties for manufacturing, fill/finish, materials, and services. Capacity expansion, process validation, regulatory approval, and qualification of alternatives take time and investment; failures or inspection findings can disrupt supply, trials, or launches. Bulk manufacturing at its Limerick, Ireland facility was temporarily interrupted during Q1 and Q2 2026 for unanticipated repairs. The company has received multiple CRLs in recent years tied to third-party fill/finish inspection findings. Delayed or unsuccessful launches could also leave excess inventory or unused capacity.

Financial, policy, and operational risks

Debt may constrain borrowing flexibility and use funds otherwise available for R&D or business development. Investments are exposed to interest-rate, liquidity, market, and issuer-credit risks. Regeneron also faces foreign-exchange, tax, cybersecurity, data-privacy, AI, talent, acquisition-integration, and public-health risks; it reports prior cybersecurity incidents but says they have not had a material adverse operational impact to date. A multi-year ERP implementation is in its early stages and could disrupt operations or fail to deliver expected efficiencies.

Trade policy is evolving. New tariffs and investigations could increase costs for imported products and inputs or prompt retaliation. Section 301 investigations begun in 2026 cover forced labor, industrial overcapacity, intellectual-property enforcement, and pharmaceutical pricing. Forced-labor tariffs of 10% or 12.5% took effect on imports from 60 countries in July 2026; exemptions for specified pharmaceutical-use articles limit, but do not eliminate, exposure. Other investigation outcomes remain uncertain.

Regeneron is subject to healthcare-law and government-pricing compliance requirements, product-liability claims, and government investigations and proceedings, including civil proceedings involving the DOJ and the U.S. Attorney’s Office for the District of Massachusetts. Adverse outcomes could result in penalties, damages, reimbursement exclusion, or restrictions. International expansion increases exposure to foreign regulation, geopolitical disruption, and anti-bribery rules.

Stock ownership and capital returns

As of September 30, 2026, the five largest shareholders plus CEO Leonard Schleifer beneficially owned approximately 31.3% of common shares and 40.0% of combined voting power, on the stated assumptions. Class A shares carry ten votes each; Class A holders had 15.2% of combined voting power. Executive officers and directors beneficially owned 5.2% of common shares and 17.6% of combined voting power. Concentrated ownership and dual-class voting may influence significant transactions, while large shareholder sales could pressure the share price. A putative federal securities class action was filed in July 2026.

The board authorized up to $3.0B in repurchases in April 2026, with $2.157B remaining at September 30, 2026. Repurchases and dividends, initiated in 2025, are discretionary and may be reduced or discontinued. Charter and legal provisions may deter or delay a change of control; the staggered board is being phased out, with annual election of all directors beginning in 2028.

During the three months ended September 30, 2026, no director or executive officer adopted, modified, or terminated a trading arrangement intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c).